Novartis: Data Proves Glivec is Superior Treatment for Patients Newly Diagnosed with Chronic Myeloid Leukemia
March 13, 2003 02:52 ET
|
Novartis
BASEL, Switzerland, March 13, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) today announced nearly three-quarters of patients achieve major treatment goal in study comparing Glivec(R) with traditional...
Novartis Divests Tension Headache Products in U.S.
February 12, 2003 03:15 ET
|
Novartis
BASEL, Switzerland, Feb. 12, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today that it has sold the U.S. rights for its Fioricet(R) and Fiorinal(R) product lines to Watson Pharmaceuticals,...
Novartis Meets Full-Year Double-Digit Sales Growth Objective with Strong Operating Performance in 2002
January 23, 2003 01:52 ET
|
Novartis
BASEL, Switzerland, Jan. 23, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS):
-- Group sales up 11% in local currencies (2% in CHF) thanks to strong
volume growth in Pharmaceuticals and Generics
...
Novartis Communication Launches a New Online Media Database -- http://mediadepot.novartis.com
January 22, 2003 05:24 ET
|
Novartis
BASEL, Switzerland, Jan. 22, 2003 -- Novartis (NYSE:NVS) today unveils its new media database "media depot." At http://mediadepot.novartis.com more than 700 printable photographs, documents, video...
Novartis International AG: 2002 Financial Results
January 22, 2003 04:54 ET
|
Novartis
BASEL, Switzerland, Jan. 22, 2003 (PRIMEZONE) -- Novartis International AG (NYSE:NVS):
Please note that we will publish our 2002 financial results on Thursday, January 23, 2003 at approximately...
Novartis to Unite Its Generics Businesses Under One Single Global Brand: Sandoz
January 21, 2003 05:05 ET
|
Novartis
BASEL, Switzerland and KUNDL, Austria, Jan. 21, 2002 (PRIMEZONE) -- Novartis (NYSE:NVS) today unveiled plans to unite its 14 Generics company brands under a single global umbrella name, "Sandoz," to...